Ribonucleotide reductase inhibitor
Ribonucleotide reductase inhibitors are a family of anti-cancer drugs that interfere with the growth of tumor cells by blocking the formation of deoxyribonucleotides (building blocks of DNA).
Examples include:
- motexafin gadolinium.[1]
- hydroxyurea[2]
- fludarabine, cladribine, gemcitabine, tezacitabine, and triapine[3]
- gallium maltolate, gallium nitrate[4]
See also
References
- ↑ Zahedi Avval F, Berndt C, Pramanik A, Holmgren A (January 2009). "Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd)". Biochem. Biophys. Res. Commun. 379 (3): 775–9. doi:10.1016/j.bbrc.2008.12.128. PMID 19121624.
- ↑ Mayhew CN, Phillips JD, Cibull ML, Elford HL, Gallicchio VS (September 2002). "Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea". Antivir. Chem. Chemother. 13 (5): 305–14. PMID 12630679.
- ↑ Tsimberidou AM, Alvarado Y, Giles FJ (August 2002). "Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies". Expert Rev Anticancer Ther 2 (4): 437–48. doi:10.1586/14737140.2.4.437. PMID 12647987.
- ↑ Bernstein LR (1998). "Mechanisms of therapeutic activity for gallium" (PDF). Pharmacol. Rev. 50 (4): 665–682. PMID 9860806.
External links
- Ribonucleotide reductase inhibitor entry in the public domain NCI Dictionary of Cancer Terms
This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".
| ||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Wednesday, January 29, 2014. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.